1
|
Dedeloudi A, Martinez-Marcos L, Quinten T, Andersen S, Lamprou DA. Biopolymeric 3D printed implantable scaffolds as a potential adjuvant treatment for acute post-operative pain management. Expert Opin Drug Deliv 2024:1-13. [PMID: 38555481 DOI: 10.1080/17425247.2024.2336492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 03/09/2024] [Indexed: 04/02/2024]
Abstract
BACKGROUND Pain is characterized as a major symptom induced by tissue damage occurring from surgical procedures, whose potency is being experienced subjectively, while current pain relief strategies are not always efficient in providing individualized treatment. 3D printed implantable devices hold the potential to offer a precise and customized medicinal approach, targeting both tissue engineering and drug delivery. RESEARCH DESIGN AND METHODS Polycaprolactone (PCL) and PCL - chitosan (CS) composite scaffolds loaded with procaine (PRC) were fabricated by bioprinting. Geometrical features including dimensions, pattern, and infill of the scaffolds were mathematically optimized and digitally determined, aiming at developing structurally uniform 3D printed models. Printability studies based on thermal imaging of the bioprinting system were performed, and physicochemical, surface, and mechanical attributes of the extruded scaffolds were evaluated. The release rate of PRC was examined at different time intervals up to 1 week. RESULTS Physicochemical stability and mechanical integrity of the scaffolds were studied, while in vitro drug release studies revealed that CS contributes to the sustained release dynamic of PRC. CONCLUSIONS The printing extrusion process was capable of developing implantable devices for a local and sustained delivery of PRC as a 7-day adjuvant regimen in post-operative pain management.
Collapse
Affiliation(s)
| | - Laura Martinez-Marcos
- Janssen Pharmaceutica, Oral Solids Development (OSD) Research & Development Department, Beerse, Belgium
| | - Thomas Quinten
- Janssen Pharmaceutica, Oral Solids Development (OSD) Research & Development Department, Beerse, Belgium
| | - Sune Andersen
- Janssen Pharmaceutica, Oral Solids Development (OSD) Research & Development Department, Beerse, Belgium
| | | |
Collapse
|
2
|
Li J, Li C, Zhang H, Gao X, Wang T, Wang Z, Zheng A. Preparation of Azithromycin Amorphous Solid Dispersion by Hot-Melt Extrusion: An Advantageous Technology with Taste Masking and Solubilization Effects. Polymers (Basel) 2022; 14:polym14030495. [PMID: 35160485 PMCID: PMC8840525 DOI: 10.3390/polym14030495] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 01/23/2022] [Accepted: 01/24/2022] [Indexed: 01/16/2023] Open
Abstract
Azithromycin (AZI) is one of the most commonly used macrolide antibiotics in children, but has the disadvantages of a heavy bitter taste and poor solubility. In order to solve these problems, hot-melt extrusion (HME) was used to prepare azithromycin amorphous solid dispersion. Preliminary selection of a polymer for HME was conducted by calculating Hansen solubility parameter to predict the miscibility of the drug and polymer. Eudragit® RL PO was chosen as the polymer due to its combination of taste-masking effect and dissolution. Moreover, the solubility was improved with this polymer. Design of experiments (DoE) was used to optimize the formulation and process, with screw speed, extrusion temperature, and drug percentage as independent variables, and content, dissolution, and extrudates diameter as dependent variables. The optimal extrusion parameters were obtained as follows: temperature-150 °C; screw speed-75 rpm; and drug percentage-25%. Differential scanning calorimetry (DSC) and Powder X-ray Diffraction (PXRD) studies of the powdered solid dispersions showed that the crystalline AZI transformed into the amorphous form. Fourier transform infrared spectroscopy (FTIR) results indicated that the formation of a hydrogen bond between AZI and the polymer led to the stabilization of AZI in its amorphous form. In conclusion, this work illustrated the importance of HME for the preparation of amorphous solid dispersion of AZI, which can solve the problems of bitterness and low solubility. It is also of great significance for the development of compliant pediatric AZI preparation.
Collapse
Affiliation(s)
- Jiale Li
- School of Pharmacy, Anhui Medical University, 81th Meishan Road, Hefei 230032, China;
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
| | - Conghui Li
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
| | - Hui Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
| | - Xiang Gao
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
| | - Ting Wang
- School of Pharmacy, Anhui Medical University, 81th Meishan Road, Hefei 230032, China;
- Correspondence: (T.W.); (Z.W.); (A.Z.); Tel.: +86-15155934952 (T.W.); +86-(0)10-66874665 (Z.W.); +86-(0)10-66931694 (A.Z.)
| | - Zengming Wang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
- Correspondence: (T.W.); (Z.W.); (A.Z.); Tel.: +86-15155934952 (T.W.); +86-(0)10-66874665 (Z.W.); +86-(0)10-66931694 (A.Z.)
| | - Aiping Zheng
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Haidian District, Beijing 100850, China; (C.L.); (H.Z.); (X.G.)
- Correspondence: (T.W.); (Z.W.); (A.Z.); Tel.: +86-15155934952 (T.W.); +86-(0)10-66874665 (Z.W.); +86-(0)10-66931694 (A.Z.)
| |
Collapse
|
3
|
Kovács K, Tóth T, Wojnárovits L. Evaluation of advanced oxidation processes for β-blockers degradation: a review. WATER SCIENCE AND TECHNOLOGY : A JOURNAL OF THE INTERNATIONAL ASSOCIATION ON WATER POLLUTION RESEARCH 2022; 85:685-705. [PMID: 35100147 DOI: 10.2166/wst.2021.631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
This study summarizes the results of scientific investigations on the removal of the three most often used β-blockers (atenolol, metoprolol and propranolol) by various advanced oxidation processes (AOP). The free radical chemistry, rate constants, degradation mechanism and elimination effectiveness of these compounds are discussed together with the technical details of experiments. In most AOP the degradation is predominantly initiated by hydroxyl radicals. In sulfate radical anion-based oxidation processes (SROP) both hydroxyl radicals and sulfate radical anions greatly contribute to the degradation. The rate constants of reactions with these two radicals are in the 109-1010 M-1 s-1 range. The degradation products reflect ipso attack, hydroxylation on the aromatic ring and/or the amino moiety and cleavage of the side chain. Among AOP, photocatalysis and SROP are the most effective for degradation of the three β-blockers. The operating parameters have to be optimized to the most suitable effectiveness.
Collapse
Affiliation(s)
- Krisztina Kovács
- Institute for Energy Security and Environmental Safety, Centre for Energy Research, Konkoly-Thege Miklós út 29-33, H-1121, Budapest, Hungary E-mail:
| | - Tünde Tóth
- Institute for Energy Security and Environmental Safety, Centre for Energy Research, Konkoly-Thege Miklós út 29-33, H-1121, Budapest, Hungary E-mail: ; Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111, Budapest, Hungary
| | - László Wojnárovits
- Institute for Energy Security and Environmental Safety, Centre for Energy Research, Konkoly-Thege Miklós út 29-33, H-1121, Budapest, Hungary E-mail:
| |
Collapse
|
4
|
Independent Tailoring of Dose and Drug Release via a Modularized Product Design Concept for Mass Customization. Pharmaceutics 2020; 12:pharmaceutics12080771. [PMID: 32823877 PMCID: PMC7465528 DOI: 10.3390/pharmaceutics12080771] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 08/11/2020] [Accepted: 08/12/2020] [Indexed: 12/15/2022] Open
Abstract
Independent individualization of multiple product attributes, such as dose and drug release, is a crucial overarching requirement of pharmaceutical products for individualized therapy as is the unified integration of individualized product design with the processes and production that drive patient access to such therapy. Individualization intrinsically demands a marked increase in the number of product variants to suit smaller, more stratified patient populations. One established design strategy to provide enhanced product variety is product modularization. Despite existing customized and/or modular product design concepts, multifunctional individualization in an integrated manner is still strikingly absent in pharma. Consequently, this study aims to demonstrate multifunctional individualization through a modular product design capable of providing an increased variety of release profiles independent of dose and dosage form size. To further exhibit that increased product variety is attainable even with a low degree of product modularity, the modular design was based upon a fixed target dosage form size of approximately 200 mm3 comprising two modules, approximately 100 mm3 each. Each module contained a melt-extruded and molded formulation of 40% w/w metoprolol succinate in a PEG1500 and Kollidon® VA64 erodible hydrophilic matrix surrounded by polylactic acid and/or polyvinyl acetate as additional release rate-controlling polymers. Drug release testing confirmed the generation of predictable, combined drug release kinetics for dosage forms, independent of dose, based on a product’s constituent modules and enhanced product variety through a minimum of six dosage form release profiles from only three module variants. Based on these initial results, the potential of the reconfigurable modular product design concept is discussed for unified integration into a pharmaceutical mass customization/mass personalization context.
Collapse
|
5
|
Katopodis K, Kapourani A, Vardaka E, Karagianni A, Chorianopoulou C, Kontogiannopoulos KN, Bikiaris DN, Kachrimanis K, Barmpalexis P. Partially hydrolyzed polyvinyl alcohol for fusion-based pharmaceutical formulation processes: Evaluation of suitable plasticizers. Int J Pharm 2020; 578:119121. [DOI: 10.1016/j.ijpharm.2020.119121] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Revised: 02/02/2020] [Accepted: 02/04/2020] [Indexed: 01/12/2023]
|
6
|
Yu J, Shan X, Chen S, Sun X, Song P, Zhao R, Hu L. Preparation and evaluation of novel multi-channel orally disintegrating tablets. Eur J Pharm Sci 2020; 142:105108. [DOI: 10.1016/j.ejps.2019.105108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Revised: 08/28/2019] [Accepted: 10/13/2019] [Indexed: 01/04/2023]
|
7
|
Abstract
Most of published reviews of twin-screw extrusion focused on its application for enhancing the bioavailability of amorphous solid dispersions while few of them focused on its use for manufacturing sustained-release oral dosage forms and medical implants, despite the considerable interest and success this process has garnered both in academia and in the pharmaceutical industry. Compared to conventional batch processing, twin-screw extrusion offers the advantages of continuous processing and the ability to prepare oral dosage forms and medical implants that have unique physicochemical and drug release attributes. This review provides an in-depth analysis of the formulation composition and processing conditions of twin-screw extrusion and how these factors affect the drug release properties of sustained-release dosage forms. This review also illustrates the unique advantages of this process by presenting case studies of a wide variety of commercial sustained-release products manufactured using twin-screw extrusion.
Collapse
|
8
|
Rapid Preparation of Spherical Granules via the Melt Centrifugal Atomization Technique. Pharmaceutics 2019; 11:pharmaceutics11050198. [PMID: 31052257 PMCID: PMC6572516 DOI: 10.3390/pharmaceutics11050198] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2019] [Revised: 04/18/2019] [Accepted: 04/18/2019] [Indexed: 01/28/2023] Open
Abstract
Granules with superior fluidity and low moisture absorption are ideal for tableting and capsule filling. Melt granulation as a solvent-free technology has attracted increasing interest for the granulation of moisture-sensitive drugs. The objective of the present study was to develop a solvent-less and high throughput melt granulation method via the melt centrifugal atomization (MCA) technique. The granule formability of various drugs and excipients via MCA and their dissolution properties were studied. It was found that the yield, fluidity, and moisture resistance of the granules were affected by the drug and excipient types, operation temperature, and collector diameter. The drugs were in an amorphous state in pure drug granules, or were highly dispersed in excipients as solid dispersions. The granules produced via MCA showed an improved drug dissolution. The present study demonstrated that the solvent-free, one-step, and high-throughput MCA approach can be used to produce spherical granules with superior fluidity and immediate drug release characteristics for poorly water-soluble and moisture-sensitive therapeutics.
Collapse
|
9
|
Fuenmayor E, Forde M, Healy AV, Devine DM, Lyons JG, McConville C, Major I. Comparison of fused-filament fabrication to direct compression and injection molding in the manufacture of oral tablets. Int J Pharm 2019; 558:328-340. [PMID: 30659922 DOI: 10.1016/j.ijpharm.2019.01.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Revised: 01/09/2019] [Accepted: 01/11/2019] [Indexed: 01/12/2023]
Abstract
Oral tablets are a convenient form to deliver active pharmaceutical ingredients (API) and have a high level of acceptance from clinicians and patients. There is a wide range of excipients available for the fabrication of tablets thereby offering a versatile platform for the delivery of therapeutic agents to the gastrointestinal tract. However, the geometry of tablets is limited by conventional manufacturing processes. This study aimed to compare three manufacturing processes in the production of flat-faced oral tablets using the same formulation composed of a polymer blend and caffeine as a model drug: fused-filament fabrication (FFF), direct compression (DC) and injection molding (IM). Hot-melt extrusion was used to convert a powder blend into feedstock material for FFF and IM processes, while DC was performed on the powder mixture. Tablets were produced with the same dimensions and were characterized for their physical and dissolution properties. There were statistical differences in the physical properties and drug release profiles of the tablets produced by the different manufacturing processes. DC tablets displayed immediate release, IM provided sustained release over 48 h, and FFF tablets displayed both release types depending on the printing parameters. FFF continues to demonstrate high potential as a manufacturing process for the efficient production of personalized oral tablets.
Collapse
Affiliation(s)
- Evert Fuenmayor
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland
| | - Martin Forde
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland
| | - Andrew V Healy
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland
| | - Declan M Devine
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland
| | - John G Lyons
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland
| | - Christopher McConville
- School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, UK
| | - Ian Major
- Materials Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Ireland.
| |
Collapse
|
10
|
Korte C, Quodbach J. 3D-Printed Network Structures as Controlled-Release Drug Delivery Systems: Dose Adjustment, API Release Analysis and Prediction. AAPS PharmSciTech 2018; 19:3333-3342. [PMID: 29855799 DOI: 10.1208/s12249-018-1017-0] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 04/11/2018] [Indexed: 11/30/2022] Open
Abstract
3D printing evolved as a promising technique to improve individualization of drug therapy. In particular, when printing sustained release solid dosage forms, as for instance implants, inserts, and also tablets, estimation of the drug release profile in vivo is necessary. In most cases, corresponding analyses cannot be performed at hospital or community pharmacies. Therefore, the present study aimed to develop a sustained release drug delivery system produced via 3D printing, which allows dose adaption and estimation of drug release at the same time. Filaments as feedstock for the printer were produced via hot-melt extrusion and consisted of Eudragit® RL as sustained release polymer, 30% theophylline as model active pharmaceutical ingredient, and stearic acid as solid plasticizer. Assuming that the surface/mass ratio was constant, network structures of different densities were printed as novel solid dosage form. Their weight (263 to 668 mg), thereby their dose, and surface area, determined using X-ray microcomputed tomography, showed a linear correlation with the fill density. The specific surface area of the network hardly varied with changing fill density. Dissolution studies showed a slower drug release for dosage forms with a denser network. Higuchi's model was used for prediction of drug release and showed limited applicability due to different release kinetics for different fill densities. However, using linear interpolation for the prediction resulted in good RMSEP values between 1.4 and 3.7%. These findings might be useful to enable customized production of sustained release solid dosage forms via 3D printing in hospital and community pharmacies in the future.
Collapse
|
11
|
Extended release delivery system of metoprolol succinate using hot-melt extrusion: effect of release modifier on methacrylic acid copolymer. Drug Deliv Transl Res 2018; 8:1679-1693. [DOI: 10.1007/s13346-018-0545-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
12
|
Shetab Boushehri MA, Stein V, Lamprecht A. Cargo-free particles of ammonio methacrylate copolymers: From pharmaceutical inactive ingredients to effective anticancer immunotherapeutics. Biomaterials 2018. [DOI: 10.1016/j.biomaterials.2018.02.053] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Development of Maltodextrin-Based Immediate-Release Tablets Using an Integrated Twin-Screw Hot-Melt Extrusion and Injection-Molding Continuous Manufacturing Process. J Pharm Sci 2017; 106:3328-3336. [DOI: 10.1016/j.xphs.2017.06.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Revised: 05/31/2017] [Accepted: 06/19/2017] [Indexed: 01/03/2023]
|
14
|
Desai PM, Hogan RC, Brancazio D, Puri V, Jensen KD, Chun JH, Myerson AS, Trout BL. Integrated hot-melt extrusion – injection molding continuous tablet manufacturing platform: Effects of critical process parameters and formulation attributes on product robustness and dimensional stability. Int J Pharm 2017; 531:332-342. [DOI: 10.1016/j.ijpharm.2017.08.097] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 08/17/2017] [Accepted: 08/20/2017] [Indexed: 02/08/2023]
|
15
|
Patil H, Tiwari RV, Repka MA. Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation. AAPS PharmSciTech 2016; 17:20-42. [PMID: 26159653 PMCID: PMC4766118 DOI: 10.1208/s12249-015-0360-7] [Citation(s) in RCA: 269] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 06/19/2015] [Indexed: 11/30/2022] Open
Abstract
Hot-melt extrusion (HME) is a promising technology for the production of new chemical entities in the developmental pipeline and for improving products already on the market. In drug discovery and development, industry estimates that more than 50% of active pharmaceutical ingredients currently used belong to the biopharmaceutical classification system II (BCS class II), which are characterized as poorly water-soluble compounds and result in formulations with low bioavailability. Therefore, there is a critical need for the pharmaceutical industry to develop formulations that will enhance the solubility and ultimately the bioavailability of these compounds. HME technology also offers an opportunity to earn intellectual property, which is evident from an increasing number of patents and publications that have included it as a novel pharmaceutical formulation technology over the past decades. This review had a threefold objective. First, it sought to provide an overview of HME principles and present detailed engineered extrusion equipment designs. Second, it included a number of published reports on the application of HME techniques that covered the fields of solid dispersions, microencapsulation, taste masking, targeted drug delivery systems, sustained release, films, nanotechnology, floating drug delivery systems, implants, and continuous manufacturing using the wet granulation process. Lastly, this review discussed the importance of using the quality by design approach in drug development, evaluated the process analytical technology used in pharmaceutical HME monitoring and control, discussed techniques used in HME, and emphasized the potential for monitoring and controlling hot-melt technology.
Collapse
Affiliation(s)
- Hemlata Patil
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA
| | - Roshan V Tiwari
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA.
- Pii Center for Pharmaceutical Technology, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.
| |
Collapse
|
16
|
Sarraf AG, Cherkaoui S, Jordan O, Gurny R, Doelker E. Controlled drug release from melt-extrudates through processing parameters: A chemometric approach. Int J Pharm 2015; 481:9-17. [PMID: 25543111 DOI: 10.1016/j.ijpharm.2014.12.046] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Revised: 12/16/2014] [Accepted: 12/19/2014] [Indexed: 11/16/2022]
Affiliation(s)
- Abraham G Sarraf
- School of Pharmaceutical Sciences, Ecole de Pharmacie Genève-Lausanne, University of Geneva, University of Lausanne, 1211 Geneva 4, Switzerland
| | | | - Olivier Jordan
- School of Pharmaceutical Sciences, Ecole de Pharmacie Genève-Lausanne, University of Geneva, University of Lausanne, 1211 Geneva 4, Switzerland
| | - Robert Gurny
- School of Pharmaceutical Sciences, Ecole de Pharmacie Genève-Lausanne, University of Geneva, University of Lausanne, 1211 Geneva 4, Switzerland
| | - Eric Doelker
- School of Pharmaceutical Sciences, Ecole de Pharmacie Genève-Lausanne, University of Geneva, University of Lausanne, 1211 Geneva 4, Switzerland.
| |
Collapse
|
17
|
Rosiaux Y, Girard JM, Desvignes F, Miolane C, Marchaud D. Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol 888 ATO. Drug Dev Ind Pharm 2015; 41:1738-44. [DOI: 10.3109/03639045.2014.1002410] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Thermoplastic polyurethanes for the manufacturing of highly dosed oral sustained release matrices via hot melt extrusion and injection molding. Eur J Pharm Biopharm 2015; 90:44-52. [DOI: 10.1016/j.ejpb.2014.11.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 11/04/2014] [Accepted: 11/07/2014] [Indexed: 11/24/2022]
|
19
|
Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach. Ther Deliv 2014; 5:817-41. [DOI: 10.4155/tde.14.39] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Use of the amorphous state is considered to be one of the most effective approaches for improving the dissolution and subsequent oral bioavailability of poorly water-soluble drugs. However as the amorphous state has much higher physical instability in comparison with its crystalline counterpart, stabilization of amorphous drugs in a solid-dosage form presents a major challenge to formulators. The currently used approaches for stabilizing amorphous drug are discussed in this article with respect to their preparation, mechanism of stabilization and limitations. In order to realize the potential of amorphous formulations, significant efforts are required to enable the prediction of formulation performance. This will facilitate the development of computational tools that can inform a rapid and rational formulation development process for amorphous drugs.
Collapse
|